Jovana Milic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jovana Milic has a total of 305 co-authors. Here are the top co-authors by number of shared publications:
- Giovanni Guaraldi
Modena HIV Cohort Università degli Studi di Modena Modena Italy
26 shared publications - Cristina Mussini
Department of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy
12 shared publications - Gianluca Cuomo
Clinic of Infectious Diseases Azienda Ospedaliero‐Universitaria Di Modena Modena Italy
8 shared publications - Erica Franceschini
Department of Infectious Diseases, Azienda Ospedaliera-Universitaria of Modena, University of Modena and Reggio Emilia, 41121 Modena, Italy
7 shared publications - Margherita Digaetano
Department of Infectious Diseases, Azienda Ospedaliera-Universitaria of Modena, University of Modena and Reggio Emilia, 41125 Modena, Italy
7 shared publications - Marianna Menozzi
Department of Infectious Diseases, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy
7 shared publications
Latest Publications
- Open Access
- 11 April 2026
- Published by Wiley in HIV Medicine
- Vol. 27 (7) , 1109-1119
A multidisciplinary, AI ‐supported quality improvement intervention to manage polypharmacy in aging people with HIV
Objectives: Aging people with HIV are increasingly affected by multimorbidity and polypharmacy, which heighten the risk of drug–drug interactions (DDIs) and potentially inappropriate medications (PIMs). This study evaluated a multidisciplinary, AI‐supported quality improvement intervention designed to optimize polypharmacy management in older people with HIV. Methods: People with HIV aged ≥50 years attending the Modena HIV Metabolic Clinic (MHMC) were invited to submit photos of their medications via WhatsApp. Images were processed by AI for optical character recognition and automatically reconciled with the electronic patient chart (EPC). AI recognition accuracy was 94% when validated against manual review. Pharmacists reviewed AI‐generated reports from the NavFarma® decision support system, generated alerts for PIM, defined according to Beers and the STOPP/START criteria, DDIs, anticholinergic burden (ACB), and risks of QTc prolongation and nephrotoxicity. Primary outcome was agreement between patient‐reported and EPC‐recorded medications. Secondary outcomes included pill burden, total prescribed drugs and actionable alerts. Results: Of 181 participants (median age 63 years; 72% male), 111 (61.3%) showed complete agreement between EPC and patient lists, while 70 (38.7%) had discrepancies. Pharmacist evaluation identified major DDIs in 70.4% of cases, ACB in 26.5%, QTc‐prolonging drugs in 81.6% and nephrotoxic agents in 95.9%. Participants with ≥10 total prescribed drugs had higher frailty, pill burden and PIM. Conclusions: AI‐assisted medication reconciliation combined with pharmacist review improved the identification of PIM and medication‐related risks, supporting safer prescribing in people with HIV. This model aligns with international calls to improve prescribing safety and offers a scalable framework for integrating digital tools into multidisciplinary HIV care.
- 11 April 2026
- Published by Wiley in HIV Medicine
- Vol. 27 (7) , 1109-1119
Open AccessA multidisciplinary, AI ‐supported quality improvement intervention to manage polypharmacy in aging people with HIV
Objectives: Aging people with HIV are increasingly affected by multimorbidity and polypharmacy, which heighten the risk of drug–drug interactions (DDIs) and potentially inappropriate medications (PIMs). This study evaluated a multidisciplinary, AI‐supported quality improvement intervention designed to optimize polypharmacy management in older people with HIV. Methods: People with HIV aged ≥50 years attending the Modena HIV Metabolic Clinic (MHMC) were invited to submit photos of their medications via WhatsApp. Images were processed by AI for optical character recognition and automatically reconciled with the electronic patient chart (EPC). AI recognition accuracy was 94% when validated against manual review. Pharmacists reviewed AI‐generated reports from the NavFarma® decision support system, generated alerts for PIM, defined according to Beers and the STOPP/START criteria, DDIs, anticholinergic burden (ACB), and risks of QTc prolongation and nephrotoxicity. Primary outcome was agreement between patient‐reported and EPC‐recorded medications. Secondary outcomes included pill burden, total prescribed drugs and actionable alerts. Results: Of 181 participants (median age 63 years; 72% male), 111 (61.3%) showed complete agreement between EPC and patient lists, while 70 (38.7%) had discrepancies. Pharmacist evaluation identified major DDIs in 70.4% of cases, ACB in 26.5%, QTc‐prolonging drugs in 81.6% and nephrotoxic agents in 95.9%. Participants with ≥10 total prescribed drugs had higher frailty, pill burden and PIM. Conclusions: AI‐assisted medication reconciliation combined with pharmacist review improved the identification of PIM and medication‐related risks, supporting safer prescribing in people with HIV. This model aligns with international calls to improve prescribing safety and offers a scalable framework for integrating digital tools into multidisciplinary HIV care.
- Open Access
- 26 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Bimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years
Older people with HIV (PWH) may benefit from long-acting cabotegravir/rilpivirine (LA-CAB/RPV), a population underrepresented in trials and observational cohorts. In the GEPPO cohort, 135 PWH >65 years of age received bimonthly LA-CAB/RPV. After 17.4 months, virological suppression (HIV-RNA <50 copies/mL) was maintained in all, while 15 participants discontinued them (11.1%, 10% in the first 12 months): 1 participant with isolated HbCAb at baseline showed a late HBV reactivation (19.4 months after starting). These findings support LA-CAB/RPV's efficacy and tolerability in older PWH.
- 26 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Open AccessBimonthly Administered Long-Acting Cabotegravir and Rilpivirine Are Highly Effective and Well-Tolerated in People With Human Immunodeficiency Virus Above 65 Years
Older people with HIV (PWH) may benefit from long-acting cabotegravir/rilpivirine (LA-CAB/RPV), a population underrepresented in trials and observational cohorts. In the GEPPO cohort, 135 PWH >65 years of age received bimonthly LA-CAB/RPV. After 17.4 months, virological suppression (HIV-RNA <50 copies/mL) was maintained in all, while 15 participants discontinued them (11.1%, 10% in the first 12 months): 1 participant with isolated HbCAb at baseline showed a late HBV reactivation (19.4 months after starting). These findings support LA-CAB/RPV's efficacy and tolerability in older PWH.
- Open Access
- 24 November 2025
- Published by Wolters Kluwer Health in AIDS
- Vol. 40 (2) , 133-142
Prevalence and risk factors of cognitive frailty in people with HIV
Background: Cognitive frailty (CF, the simultaneous presence of frailty and cognitive impairment) is recognized as a significant predictor of several adverse health outcomes. The objective of this study was to describe prevalence and risk factors for CF in people with HIV (PWH) >50 years. Methods: This was a cross-sectional observational study including PWH attending Modena HIV Metabolic Clinic (MHMC). Neurocognitive function was measured with Cogstate battery that comprises six domains. Each individual CogState raw score was transformed into z-score after correction for age and sex. Neurocognitive impairment was defined by total global deficit score >0.5. Frailty was assessed by 37-Item frailty index. Scores 0.26 as frail. Results: A total of 1258 PWH were included, 916 (73%) were males, median age was 58 years, median time since HIV diagnosis was 27 years. The sample was divided into four groups (CF) based on the presence of frailty (F) and cognitive impairment (ICT): F+/ICT+, F+/ICT−, F−/ICT+, F−/ICT−. Age per 5-year increase [odds ratio (OR) = 1.27, confidence interval (CI): 1.02–1.55, P = 0.022], nadir CD4 + cell count (OR = 0.81, CI: 0.66 – 0.99, P = 0.042) and polypharmacy (OR = 3.47, CI: 2.00–6.00, P < 0.001) were associated with CF after adjustment for time since HIV diagnosis, multimorbidity, depression and cumulative exposure to dolutegravir. Conclusion: CF prevalence in PWH >50 years was 6.8% and it is higher than what has been observed in the general population >65 years (1–4.4%). Nadir CD4 + cell count and polypharmacy was associated with CF, suggesting an HIV specific contribution related to the development of this condition.
- 24 November 2025
- Published by Wolters Kluwer Health in AIDS
- Vol. 40 (2) , 133-142
Open AccessPrevalence and risk factors of cognitive frailty in people with HIV
Background: Cognitive frailty (CF, the simultaneous presence of frailty and cognitive impairment) is recognized as a significant predictor of several adverse health outcomes. The objective of this study was to describe prevalence and risk factors for CF in people with HIV (PWH) >50 years. Methods: This was a cross-sectional observational study including PWH attending Modena HIV Metabolic Clinic (MHMC). Neurocognitive function was measured with Cogstate battery that comprises six domains. Each individual CogState raw score was transformed into z-score after correction for age and sex. Neurocognitive impairment was defined by total global deficit score >0.5. Frailty was assessed by 37-Item frailty index. Scores 0.26 as frail. Results: A total of 1258 PWH were included, 916 (73%) were males, median age was 58 years, median time since HIV diagnosis was 27 years. The sample was divided into four groups (CF) based on the presence of frailty (F) and cognitive impairment (ICT): F+/ICT+, F+/ICT−, F−/ICT+, F−/ICT−. Age per 5-year increase [odds ratio (OR) = 1.27, confidence interval (CI): 1.02–1.55, P = 0.022], nadir CD4 + cell count (OR = 0.81, CI: 0.66 – 0.99, P = 0.042) and polypharmacy (OR = 3.47, CI: 2.00–6.00, P < 0.001) were associated with CF after adjustment for time since HIV diagnosis, multimorbidity, depression and cumulative exposure to dolutegravir. Conclusion: CF prevalence in PWH >50 years was 6.8% and it is higher than what has been observed in the general population >65 years (1–4.4%). Nadir CD4 + cell count and polypharmacy was associated with CF, suggesting an HIV specific contribution related to the development of this condition.
- Open Access
Association Between Reduced Daily Protein Intake and Sarcopenic Obesity in Men Living with HIV: A New Screening Tool
Background and Aim: Sarcopenic obesity (SO) is a phenotype characterized by increased body fat combined with reduced muscle mass and strength. SO is prevalent among people living with HIV, especially in men (MLWH); however, the link between this phenotype and diet is still unclear in this population. For this reason, in this study, we aim to examine potential associations between self-reported macronutrient intake and SO in MLWH, and, eventually, to evaluate the diagnostic accuracy of a simple nutritional marker for screening SO. Methods: A total of 216 MLWH were selected from a large cohort who completed a total body composition measurement by dual-energy X-ray absorptiometry (DXA), muscle strength assessment by handgrip test, and nutritional recording by 24 h recall interview. The sample was categorized into SO (n = 45), non-SO (NSO) (n = 33), and non-sarcopenic non-obesity (NSNO) (n = 138). Logistic regression analysis was performed to determine the associations between different macronutrients and SO after adjusting for confounders. Receiver operating characteristic (ROC) curve analysis was used to identify discriminating cut-off points of the determined macronutrient intake to screen for SO. Results: The MLWH with SO while compared to NSO and NSNO, were of an older age and had a higher BMI, but with a lower total caloric and protein intake. However, adjusted logistic regression showed that only protein intake (g/kg/day) (OR = 0.017; 95%CI: 0.003–0.094, p < 0.05) and age (OR = 1.051; 95%CI: 1.011–1.093, p < 0.05) were significantly associated with SO. The age-adjusted ROC analysis identified the 0.98 g/kg/day of protein intake (AUC = 0.8149; p < 0.0001; sensitivity = 71%; specificity = 70%) as a cut-off point to screen for SO in the MLWH. Conclusions: We identified a new cut-off point of daily protein intake able to screen for SO in MLWH, and its use can be implemented in clinical settings.
Open AccessAssociation Between Reduced Daily Protein Intake and Sarcopenic Obesity in Men Living with HIV: A New Screening Tool
Background and Aim: Sarcopenic obesity (SO) is a phenotype characterized by increased body fat combined with reduced muscle mass and strength. SO is prevalent among people living with HIV, especially in men (MLWH); however, the link between this phenotype and diet is still unclear in this population. For this reason, in this study, we aim to examine potential associations between self-reported macronutrient intake and SO in MLWH, and, eventually, to evaluate the diagnostic accuracy of a simple nutritional marker for screening SO. Methods: A total of 216 MLWH were selected from a large cohort who completed a total body composition measurement by dual-energy X-ray absorptiometry (DXA), muscle strength assessment by handgrip test, and nutritional recording by 24 h recall interview. The sample was categorized into SO (n = 45), non-SO (NSO) (n = 33), and non-sarcopenic non-obesity (NSNO) (n = 138). Logistic regression analysis was performed to determine the associations between different macronutrients and SO after adjusting for confounders. Receiver operating characteristic (ROC) curve analysis was used to identify discriminating cut-off points of the determined macronutrient intake to screen for SO. Results: The MLWH with SO while compared to NSO and NSNO, were of an older age and had a higher BMI, but with a lower total caloric and protein intake. However, adjusted logistic regression showed that only protein intake (g/kg/day) (OR = 0.017; 95%CI: 0.003–0.094, p < 0.05) and age (OR = 1.051; 95%CI: 1.011–1.093, p < 0.05) were significantly associated with SO. The age-adjusted ROC analysis identified the 0.98 g/kg/day of protein intake (AUC = 0.8149; p < 0.0001; sensitivity = 71%; specificity = 70%) as a cut-off point to screen for SO in the MLWH. Conclusions: We identified a new cut-off point of daily protein intake able to screen for SO in MLWH, and its use can be implemented in clinical settings.
- Open Access
Respiratory Muscle Dysfunction and Associated Risk Factors Following COVID-19-Related Hospitalisation
Background: Studies have highlighted long-term respiratory muscle dysfunction in COVID-19 survivors, although the underlying risk factors remain unclear. This single-centre study assessed respiratory muscle function and individual associated factors at follow-up in patients hospitalised with COVID-19 and related acute respiratory failure. Methods: Data were collected for consecutive patients, aged ≥ 18 years, at the post-COVID outpatient service of Hospital Policlinico in Modena (Italy) in the time frame of 3 to 6 months after discharge. Data were analysed using single and multiple logistic regression models. Correlations among MIP/MEP, hand-grip values, and lung function were further explored. Results: Out of 223 patients (mean age 67 years, 69% male) 121 (54.3%) exhibited MIP or MEP dysfunction, which was found to be associated with the use of non-invasive ventilation (aOR = 1.91 [1.07–3.49], p = 0.04) and female gender (aOR = 1.76 [1.09–4.16], p = 0.03) as independent risk factors. A positive correlation was observed between MIP dysfunction and hand-grip strength (p = 0.03 and 0.01), whereas both MIP and MEP were significantly associated with FEV1, FVC, TLC, and DLCO. Conclusions: Respiratory muscle dysfunction is consistently prevalent and parallels peripheral muscle weakness and the lung function level in patients at follow-up after severe COVID-19. The need for non-invasive ventilation during the acute phase and female gender might represent risk factors. MIP/MEP assessment should be recommended to observe respiratory muscle dysfunction in severe post-COVID survivors.
Open AccessRespiratory Muscle Dysfunction and Associated Risk Factors Following COVID-19-Related Hospitalisation
Background: Studies have highlighted long-term respiratory muscle dysfunction in COVID-19 survivors, although the underlying risk factors remain unclear. This single-centre study assessed respiratory muscle function and individual associated factors at follow-up in patients hospitalised with COVID-19 and related acute respiratory failure. Methods: Data were collected for consecutive patients, aged ≥ 18 years, at the post-COVID outpatient service of Hospital Policlinico in Modena (Italy) in the time frame of 3 to 6 months after discharge. Data were analysed using single and multiple logistic regression models. Correlations among MIP/MEP, hand-grip values, and lung function were further explored. Results: Out of 223 patients (mean age 67 years, 69% male) 121 (54.3%) exhibited MIP or MEP dysfunction, which was found to be associated with the use of non-invasive ventilation (aOR = 1.91 [1.07–3.49], p = 0.04) and female gender (aOR = 1.76 [1.09–4.16], p = 0.03) as independent risk factors. A positive correlation was observed between MIP dysfunction and hand-grip strength (p = 0.03 and 0.01), whereas both MIP and MEP were significantly associated with FEV1, FVC, TLC, and DLCO. Conclusions: Respiratory muscle dysfunction is consistently prevalent and parallels peripheral muscle weakness and the lung function level in patients at follow-up after severe COVID-19. The need for non-invasive ventilation during the acute phase and female gender might represent risk factors. MIP/MEP assessment should be recommended to observe respiratory muscle dysfunction in severe post-COVID survivors.
- Open Access
- 12 December 2024
- Published by MDPI AG in Preprints.org
Respiratory Muscle Dysfunction and Associated Risk Factors Following COVID-19-Related Hospitalisation
Background: Studies have highlighted long-term respiratory muscle dysfunction in COVID-19 survivors, although the underlying risk factors remain unclear. This single-center study assessed respiratory muscle function and individual associated factors at follow-up in patients hospitalised with COVID-19 and related acute respiratory failure. Methods: Data were collected for consecutive patients, aged ≥18 years, at the post-COVID outpatient service of Hospital Policlinico in Modena (Italy) in the time frame of 3 to 6 months after discharge. Data were analysed using single and multiple logistic regression model. Correlation between MIP/MEP, hand-grip values and lung function were further explored. Results: Out of 223 patients (mean age 67 years, 69% male) 121 (54.3%) exhibited MIP or MEP dysfunction which was found to be associated with use of non-invasive ventilation (OR=1.93 [1.08–3.52], p=0.03) and female gender (OR=1.96 [1.1–3.57], p=0.03) as indipendent risk factors. A positive correlation was observed between MIP dysfunction and hand-grip strength (p=0.03 and 0.01), whereas both MIP and MEP were significantly associated with FEV1, FVC, TLC, and DLCO. Conclusions: Respiratory muscle dysfunction is consistently prevalent and parallels peripheral muscle weakness and lung fuction level in patients at follow up after severe COVID-19. The need for non-invasive ventilation during the acute phase and female gender might represent risk factors. MIP/MEP assessment should be recommended to observe respiratory muscle dysfunction in severe post-COVID survivors.
- 12 December 2024
- Published by MDPI AG in Preprints.org
Open AccessRespiratory Muscle Dysfunction and Associated Risk Factors Following COVID-19-Related Hospitalisation
Background: Studies have highlighted long-term respiratory muscle dysfunction in COVID-19 survivors, although the underlying risk factors remain unclear. This single-center study assessed respiratory muscle function and individual associated factors at follow-up in patients hospitalised with COVID-19 and related acute respiratory failure. Methods: Data were collected for consecutive patients, aged ≥18 years, at the post-COVID outpatient service of Hospital Policlinico in Modena (Italy) in the time frame of 3 to 6 months after discharge. Data were analysed using single and multiple logistic regression model. Correlation between MIP/MEP, hand-grip values and lung function were further explored. Results: Out of 223 patients (mean age 67 years, 69% male) 121 (54.3%) exhibited MIP or MEP dysfunction which was found to be associated with use of non-invasive ventilation (OR=1.93 [1.08–3.52], p=0.03) and female gender (OR=1.96 [1.1–3.57], p=0.03) as indipendent risk factors. A positive correlation was observed between MIP dysfunction and hand-grip strength (p=0.03 and 0.01), whereas both MIP and MEP were significantly associated with FEV1, FVC, TLC, and DLCO. Conclusions: Respiratory muscle dysfunction is consistently prevalent and parallels peripheral muscle weakness and lung fuction level in patients at follow up after severe COVID-19. The need for non-invasive ventilation during the acute phase and female gender might represent risk factors. MIP/MEP assessment should be recommended to observe respiratory muscle dysfunction in severe post-COVID survivors.
- Open Access
Bone Mineral Density and Trabecular Bone Score Changes throughout Menopause in Women with HIV
Objective: The objectives of this study were to describe the trajectories of bone mineral density (BMD) and trabecular bone score (TBS) changes throughout pre-menopause (reproductive phase and menopausal transition) and post-menopause (early and late menopause) in women with HIV (WWH) undergoing different antiretroviral therapies (ARTs) and explore the risk factors associated with those changes. Methods: This was an observational longitudinal retrospective study in WWH with a minimum of two DEXA evaluations comprising BMD and TBS measurements, both in the pre-menopausal and post-menopausal periods. Menopause was determined according to the STRAW+10 criteria, comprising four periods: the reproductive period, menopausal transition, and early- and late-menopausal periods. Mixed-effects models were fitted to estimate the trajectories of the two outcomes (BMD and TBS) over time. Annualized lumbar BMD and TBS absolute and percentage changes were calculated in each STRAW+10 time window. A backward elimination procedure was applied to obtain the final model, including the predictors that affected the trajectories of BMD or TBS over time. Results: A total of 202 WWH, all Caucasian, were included. In detail, 1954 BMD and 195 TBS data were analyzed. The median number of DEXA evaluations per woman was 10 (IQR: 7, 12). The median observation periods per patient were 12.0 years (IQR = 8.9–14.4) for BMD and 6.0 years (IQR: 4.3, 7.9) for TBS. The prevalence of osteopenia (63% vs. 76%; p < 0.001) and osteoporosis (16% vs. 36%; p < 0.001) increased significantly between the pre-menopausal and post-menopausal periods. Both BMD (1.03 (±0.14) vs. 0.92 (±0.12) g/cm2; p < 0.001) and TBS (1.41 (IQR: 1.35, 1.45) vs. 1.32 (IQR: 1.28, 1.39); p < 0.001) decreased significantly between the two periods. The trend in BMD decreased across the four STRAW+10 periods, with a slight attenuation only in the late-menopausal period when compared with the other intervals. The TBS slope did not significantly change throughout menopause. The delta mean values of TBS in WWH were lower between the menopausal transition and reproductive period compared with the difference between menopause and menopausal transition. Conclusions: Both BMD and TBS significantly decreased over time. The slope of the change in BMD and TBS significantly decreased in the menopausal transition, suggesting that this period should be considered by clinicians as a key time during which to assess bone health and modifiable risk factors in WWH.
Open AccessBone Mineral Density and Trabecular Bone Score Changes throughout Menopause in Women with HIV
Objective: The objectives of this study were to describe the trajectories of bone mineral density (BMD) and trabecular bone score (TBS) changes throughout pre-menopause (reproductive phase and menopausal transition) and post-menopause (early and late menopause) in women with HIV (WWH) undergoing different antiretroviral therapies (ARTs) and explore the risk factors associated with those changes. Methods: This was an observational longitudinal retrospective study in WWH with a minimum of two DEXA evaluations comprising BMD and TBS measurements, both in the pre-menopausal and post-menopausal periods. Menopause was determined according to the STRAW+10 criteria, comprising four periods: the reproductive period, menopausal transition, and early- and late-menopausal periods. Mixed-effects models were fitted to estimate the trajectories of the two outcomes (BMD and TBS) over time. Annualized lumbar BMD and TBS absolute and percentage changes were calculated in each STRAW+10 time window. A backward elimination procedure was applied to obtain the final model, including the predictors that affected the trajectories of BMD or TBS over time. Results: A total of 202 WWH, all Caucasian, were included. In detail, 1954 BMD and 195 TBS data were analyzed. The median number of DEXA evaluations per woman was 10 (IQR: 7, 12). The median observation periods per patient were 12.0 years (IQR = 8.9–14.4) for BMD and 6.0 years (IQR: 4.3, 7.9) for TBS. The prevalence of osteopenia (63% vs. 76%; p < 0.001) and osteoporosis (16% vs. 36%; p < 0.001) increased significantly between the pre-menopausal and post-menopausal periods. Both BMD (1.03 (±0.14) vs. 0.92 (±0.12) g/cm2; p < 0.001) and TBS (1.41 (IQR: 1.35, 1.45) vs. 1.32 (IQR: 1.28, 1.39); p < 0.001) decreased significantly between the two periods. The trend in BMD decreased across the four STRAW+10 periods, with a slight attenuation only in the late-menopausal period when compared with the other intervals. The TBS slope did not significantly change throughout menopause. The delta mean values of TBS in WWH were lower between the menopausal transition and reproductive period compared with the difference between menopause and menopausal transition. Conclusions: Both BMD and TBS significantly decreased over time. The slope of the change in BMD and TBS significantly decreased in the menopausal transition, suggesting that this period should be considered by clinicians as a key time during which to assess bone health and modifiable risk factors in WWH.
- Open Access
- 16 October 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1279390
Evaluating immunological and inflammatory changes of treatment-experienced people living with HIV switching from first-line triple cART regimens to DTG/3TC vs. B/F/TAF: the DEBATE trial
Background: The aim of this randomized clinical trial (RCT) was to compare immunological changes in virally suppressed people living with HIV (PLWH) switching from a three-drug regimen (3DR) to a two-drug regimen (2DR).Methods: An open-label, prospective RCT enrolling PLWH receiving a 3DR who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir/lamivudine (DTG/3TC) was performed. Blood was taken at baseline and months 6 and 12. The primary outcome was the change in CD4+ or CD8+ T-cell counts and CD4/CD8 ratio over time points. The secondary outcomes were the changes in immunological and inflammatory parameters. Parametric mixed-linear models with random intercepts and slopes were fitted separately for each marker after controlling for potential confounders.Results: Between the two arms (33 PLWH each), there was no difference in CD4+ or CD8+ T cells, CD4/CD8 ratio, and IL-6 trajectories. PLWH switching to DTG/3TC had increased levels of both transitional memory and terminally differentiated CD4+ T cells (arm–time interaction p-value = 0.02) and to a lesser extent for the corresponding CD8+ T-cell subsets (p = 0.09). Significantly lower levels of non-classical monocytes were detected in the B/F/TAF arm at T6 (diff = −6.7 cells/mm3; 95% CI; −16, +2.6; p-value for interaction between arm and time = 0.03). All differences were attenuated at T12.Conclusion: No evidence for a difference in absolute CD4+ and CD8+ T-cell counts, CD4/CD8 ratio, and IL-6 trajectories by study arm over 12 months was found. PLWH on DTG/3TC showed higher levels of terminally differentiated and exhausted CD4+ and CD8+ T lymphocytes and non-classical monocytes at T6. Further studies are warranted to better understand the clinical impact of our results.Clinical Trial Registration: https://clinicaltrials.gov, identifier NCT04054089.
- 16 October 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1279390
Open AccessEvaluating immunological and inflammatory changes of treatment-experienced people living with HIV switching from first-line triple cART regimens to DTG/3TC vs. B/F/TAF: the DEBATE trial
Background: The aim of this randomized clinical trial (RCT) was to compare immunological changes in virally suppressed people living with HIV (PLWH) switching from a three-drug regimen (3DR) to a two-drug regimen (2DR).Methods: An open-label, prospective RCT enrolling PLWH receiving a 3DR who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir/lamivudine (DTG/3TC) was performed. Blood was taken at baseline and months 6 and 12. The primary outcome was the change in CD4+ or CD8+ T-cell counts and CD4/CD8 ratio over time points. The secondary outcomes were the changes in immunological and inflammatory parameters. Parametric mixed-linear models with random intercepts and slopes were fitted separately for each marker after controlling for potential confounders.Results: Between the two arms (33 PLWH each), there was no difference in CD4+ or CD8+ T cells, CD4/CD8 ratio, and IL-6 trajectories. PLWH switching to DTG/3TC had increased levels of both transitional memory and terminally differentiated CD4+ T cells (arm–time interaction p-value = 0.02) and to a lesser extent for the corresponding CD8+ T-cell subsets (p = 0.09). Significantly lower levels of non-classical monocytes were detected in the B/F/TAF arm at T6 (diff = −6.7 cells/mm3; 95% CI; −16, +2.6; p-value for interaction between arm and time = 0.03). All differences were attenuated at T12.Conclusion: No evidence for a difference in absolute CD4+ and CD8+ T-cell counts, CD4/CD8 ratio, and IL-6 trajectories by study arm over 12 months was found. PLWH on DTG/3TC showed higher levels of terminally differentiated and exhausted CD4+ and CD8+ T lymphocytes and non-classical monocytes at T6. Further studies are warranted to better understand the clinical impact of our results.Clinical Trial Registration: https://clinicaltrials.gov, identifier NCT04054089.
- 15 July 2023
- Published by Wolters Kluwer Health in AIDS
- Vol. 37 (9) , 1467-1469
Moving from the prediction of fractures to the prediction of falls in an aging HIV scenario
- 15 July 2023
- Published by Wolters Kluwer Health in AIDS
- Vol. 37 (9) , 1467-1469
Moving from the prediction of fractures to the prediction of falls in an aging HIV scenario